RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Adding selegiline or zonisamide to levodopa

Researchers are comparing medicine combinations for Parkinson's over a year of treatment.

Testing a treatment or activity · Study reference: JPRN-UMIN000022533

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported date)
2016-06-01

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Ages 55years-old to 80years-old · Ask the team who can join

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: male and female

Inclusion criteria: 1). Those who are at age between 55 and 79 years. 2).The patients should be within 3 years after the onset of motor symptoms 3). The patients should be treated with levodopa/DCI within 3 months and with levodopa/DCI exclusively one month right before starting the trial. 4) The dose of levodopa/DCI should be taken from 150mg/day to 300mg/day. 5)The participant's score of MMSE should be 24 or higher. 6) The patient should be judged by attendant doctor to be appropriate for registration. 7) The agreement with the study should be obtained by the document, Exclusion criteria: Those who matched the following conditions should be excluded. 1). Those who had been treated with the anti-parkinsonian drugs except levodopa/DCI for more than 1month. 2).Those who are in pregnancy, or possible to be pregnant or those who are in the breast-feeding. 3) Those who have taken antidepressant and/or anti-psychotic drugs. 4) Those who have a history of stroke and cerebrovascular disorders. 5) Those who had a history of epilepsy or those who are in treatment of epilepsy 6) Those who have a history of alcohol intoxication, or have the treatment for alcoholic abuse 7) Those who have severe comorbidity( liver dysfunction, renal dysfunction and endocrinological disorders). 8) Those who have a familial history of Parkinson's disease 9) Those who have a history of allergic reaction with 123I- ioflupane.
Full study name & original research details

Official study title

A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease - The DAT-SPECT study for the benefit of Selegilline or Zonisamide in Parkinson's Disease(DATSZ-PD study)

Short title used by the registry

A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease

Original description

Intervention: L-Dopa/DCI only The drug is administered per oral at 150 to 300 mg/day. The treatment is started within 14days after registration and continued until day 365. L-Dopa/DCI + selegiline L-Dopa/DCI is administered per oral at 150 to 300 mg/day and selegiline is administered at 5mg/day. The treatment is started within 14days after registration and continued until day 365. L-Dopa/DCI + zonisamide L-Dopa/DCI is administered per oral at 150 to 300 mg/day and zonisamide is administered at 25mg/day. The treatment is started within 14days after registration and continued until day 365. Primary outcome: The neuroprotective effect is evaluated by 123I-FP-CIT SPECT after 1 year. Secondary outcome: The clinical symptoms are evaluated by UPDRS partII, UPDRS partIII, PDQ-39

Conditions reported: Parkinson's disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
L-Dopa/DCI only The drug is administered per oral at 150 to 300 mg/day. The treatment is started within 14days after registration and continued until day 365. L-Dopa/DCI + selegiline L-Dopa/DCI is administered per oral at 150 to 300 mg/day and selegiline is administered at 5mg/day. The treatment is started within 14days after registration and continued until day 365. L-Dopa/DCI + zonisamide L-Dopa/DCI is administered per oral at 150 to 300 mg/day and zonisamide is administered at 25mg/day. The treatment is started within 14days after registration and continued until day 365.
Phases
Phase II
Sponsor
Osaka Redcross Hospital Wakayama Prefectural Medical College
Start date reported by registry
2016-06-01 (reported)

Registry updated: Not reported · Status last verified by the registry submitter: Not reported

Registry records retrieved 2026-10-14 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Hidefumi Ito · 073-447-2300 · itohid@kuhp.kyoto-u.ac.jp

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Facility not reported

Japan

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.